CDH2 and glioblastoma: Recent study demonstrates MIR155HG is highly expressed in mesenchymal GBM tissues and suppression of MIR155HG can decrease expression of mesenchymal transition-associated proteins, such as β-catenin, N-cadherin, suggesting a function as a regulator in mesenchymal transition progression [31].